Natus Medical Incorporated (NASDAQ:NTUS) CEO Jonathan Kennedy sold 8,676 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $32.65, for a total value of $283,271.40.
Shares of Natus Medical stock traded up $0.14 during trading hours on Wednesday, hitting $31.60. 176,517 shares of the company’s stock traded hands, compared to its average volume of 248,599. Natus Medical Incorporated has a 12-month low of $22.25 and a 12-month high of $34.89. The stock’s fifty day moving average is $32.40. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.87 and a quick ratio of 1.36. The stock has a market capitalization of $1.09 billion, a PE ratio of 22.25 and a beta of 0.68.
Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.36 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.38 by ($0.02). The business had revenue of $123.46 million for the quarter, compared to the consensus estimate of $124.75 million. Natus Medical had a negative net margin of 4.71% and a positive return on equity of 10.43%. The business’s revenue was down 5.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.40 EPS. Sell-side analysts anticipate that Natus Medical Incorporated will post 1.26 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on NTUS. TheStreet upgraded Natus Medical from a “d+” rating to a “c-” rating in a report on Monday, September 30th. Zacks Investment Research lowered Natus Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 9th.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.